ISRE-Luc/EF1α-mCherry Reporter Cell Line - SGC-7901

The ISRE-Luc/EF1α-mCherry Reporter Cell Line - SGC-7901 is a specialized genetic tool derived from the SGC-7901 human gastric adenocarcinoma lineage, a well-established model in oncology and gastrointestinal research. This dual-reporter system integrates two distinct expression cassettes to provide a robust platform for real-time monitoring of cellular signaling. The first cassette features the Firefly Luciferase gene under the transcriptional control of the Interferon-Stimulated Response Element (ISRE), which serves as a sensitive biosensor for the activation of the JAK-STAT signaling pathway and the presence of Type I or Type III interferons. Complementing this, the cell line constitutively expresses the mCherry fluorescent protein under the control of the EF1α promoter. This secondary reporter functions as a vital internal control for cell viability, normalization of experimental data, and live-cell imaging, ensuring that variations in cell density or growth conditions are accurately accounted for during quantitative assays.

This reporter cell line is primarily utilized in the study of innate immunity and the high-throughput screening of antiviral or anti-tumor therapeutics. Since the ISRE promoter specifically responds to interferon-alpha (IFN-α) and interferon-beta (IFN-β), researchers can utilize the luciferase signal to quantify the potency of exogenous cytokines or evaluate the inhibitory effects of small molecule drugs on the JAK-STAT axis. Furthermore, given its origin in gastric cancer cells, the line is particularly valuable for investigating the complex interactions between inflammatory signals and tumor progression in the stomach. The constitutive mCherry signal allows for dual-parameter analysis, where one can simultaneously observe morphological changes or cell proliferation alongside the activation of inflammatory pathways. This makes the SGC-7901 reporter line an ideal candidate for large-scale pharmaceutical screening, the characterization of novel biologics, and mechanistic studies regarding how gastric cancer cells evade the immune system or respond to targeted immunotherapies.